However, reduction of therapeutic effect by the soluble CD30 appears unlikely since the immunotoxin is administered in excess as compared to the minimal amount of native anti‐CD30 monoclonal antibody that has been shown to target tumor cells in vivo [35]. The gene discussed is TNFRSF8; the disease is neoplasm.